Guanine

Guanine

SCHEMBL4460112

Cc1c[nH]c(=O)[nH]c1=O.Nc1nc2[nH]cnc2c(=O)[nH]1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.51
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
GLA P06280 1/20 0.46
PMP22 Q01453 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PNP P00491 2/20 0.40
XDH P47989 1/20 0.38
DYRK1A Q13627 1/20 0.37
MAPT P10636 1/20 0.36
MITF O75030 1/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
HBB P68871 1/20 0.36
HIF1A Q16665 1/20 0.36
CYP1A2 P05177 1/20 0.35
PDPK1 O15530 2/20 0.34
PARP1 P09874 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Guanine SCHEMBL4577873 0.92 ATAD2 (0.43) ATAD2KDM4EALDH1A1LMNAGLA
Guanine SCHEMBL4007020 0.90 ATAD2 (0.41) ATAD2KDM4EALDH1A1LMNAGLA
Guanine SCHEMBL17542295 0.84 ATAD2 (0.36) ATAD2KDM4EALDH1A1LMNAGLA
Guanine SCHEMBL4658042 0.84 ALDH1A1 (0.61) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL5259 0.84 ALDH1A1 (0.61) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL7513533 0.84 KDM4E (0.46) KDM4EALDH1A1LMNAGLAPMP22
Guanine SCHEMBL5097008 0.84 ATAD2 (0.36) ATAD2KDM4EALDH1A1LMNAGLA
Guanine SCHEMBL9468293 0.83 ATAD2 (0.35) ATAD2KDM4EALDH1A1LMNAGLA
2,6-Diaminopurine SCHEMBL1672826 0.83 ATAD2 (0.50) ATAD2PNPPDPK1PARP1ACHE
Guanine SCHEMBL4301039 0.83 KDM4E (0.44) KDM4EALDH1A1LMNAGLAPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521178-B1 Method for synthesizing DNA TAKARA BIO INC. (JP) 2009-04-21 US claimed
US-7034133-B2 Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance EXIQON A/S (DK) 2006-04-25 US claimed
US-6670461-B1 Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. EXIQON A/S (DK) 2003-12-30 US claimed
US-20030208061-A1 Labeled oligonucleotides, methods for making same, and compounds useful therefor ISIS PHARMACEUTICALS, INC. 2003-11-06 US claimed
CN-115491418-A Second-generation sequencing panel of target genes with congenital incomplete lens dislocation and sequencing method 复旦大学附属眼耳鼻喉科医院 2022-12-20 CN disclosed
US-11279736-B2 Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids CARNEGIE MELLON UNIVERSITY (US) 2022-03-22 US disclosed
US-20210214397-A1 CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS CARNEGIE MELLON UNIVERSITY (US) 2021-07-15 US disclosed
CN-111867626-A Methods and compositions for treating amyloid deposition diseases 纽约哥伦比亚大学理事会 2020-10-30 CN disclosed
US-20060141511-A1 Chemical amplification for the synthesis of patterned arrays AFFYMETRIX, INC (US) 2006-06-29 US disclosed
US-20050181421-A1 Methods of array synthesis AFFYMETRIX, INC. (US) 2005-08-18 US disclosed
EP-1559785-A1 Oligo- or polynucleotides for achieving RNA interference in mammalian cells Bio-Think Tank Co., Ltd. (JP) 2005-08-03 EP disclosed
US-6770436-B1 RADIATION-ACTIVATED CATALYSTS (RACS), AUTOCATALYTIC REACTIONS, AND PROTECTIVE GROUPS ARE EMPLOYED TO ACHIEVE A HIGHLY SENSITIVE, HIGH RESOLUTION, RADIATION DIRECTED COMBINATORIAL SYNTHESIS OF PATTERN ARRAYS OF DIVERSE POLYMERS AFFYMETRIX, INC. 2004-08-03 US disclosed
US-20020122874-A1 Process for preparing peptide nucleic acid probe using polymeric photoacid generator SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-09-05 US disclosed
WO-1997001634-A3 POLYPEPTIDE FOR REPAIRING GENETIC INFORMATION, NUCLEOTIDIC SEQUENCE WHICH CODES FOR IT AND PROCESS FOR THE PREPARATION THEREOF (GUANINE THYMINE BINDING PROTEIN - GTBP) ANGELETTI P IST RICHERCHE BIO (IT) 1997-04-03 WO disclosed
WO-1997001634-A3 POLYPEPTIDE FOR REPAIRING GENETIC INFORMATION, NUCLEOTIDIC SEQUENCE WHICH CODES FOR IT AND PROCESS FOR THE PREPARATION THEREOF (GUANINE THYMINE BINDING PROTEIN - GTBP) ANGELETTI P IST RICHERCHE BIO (IT) 1997-04-03 WO disclosed
WO-1997001634-A2 POLYPEPTIDE FOR REPAIRING GENETIC INFORMATION, NUCLEOTIDIC SEQUENCE WHICH CODES FOR IT AND PROCESS FOR THE PREPARATION THEREOF (GUANINE THYMINE BINDING PROTEIN - GTBP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 1997-01-16 WO disclosed
WO-1997001634-A2 POLYPEPTIDE FOR REPAIRING GENETIC INFORMATION, NUCLEOTIDIC SEQUENCE WHICH CODES FOR IT AND PROCESS FOR THE PREPARATION THEREOF (GUANINE THYMINE BINDING PROTEIN - GTBP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 1997-01-16 WO disclosed
WO-1997001634-A2 POLYPEPTIDE FOR REPAIRING GENETIC INFORMATION, NUCLEOTIDIC SEQUENCE WHICH CODES FOR IT AND PROCESS FOR THE PREPARATION THEREOF (GUANINE THYMINE BINDING PROTEIN - GTBP) ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 1997-01-16 WO disclosed
EP-0639200-A1 METHODS AND REAGENTS FOR CLEAVING AND DEPROTECTING OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1995-02-22 EP disclosed
WO-1993022329-A1 METHODS AND REAGENTS FOR CLEAVING AND DEPROTECTING OLIGONUCLEOTIDES BECKMAN INSTRUMENTS, INC. (US) 1993-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208061-A1 Labeled oligonucleotides, methods for making same, and compounds useful therefor METTL16, BCDIN3D, GARS1 ATAD2 4679/4885KDM4E 2851/4885ALDH1A1 1042/4885
US-20050181421-A1 Methods of array synthesis RAC2, RAC3, RAC1 ATAD2 2880/4885KDM4E 4170/4885ALDH1A1 2290/4885
US-11279736-B2 Conformationally-preorganized, MiniPEG-containing gamma-peptide nucleic acids POLL, PCNA, POLG ATAD2 2136/4885KDM4E 4658/4885ALDH1A1 4116/4885
US-20060141511-A1 Chemical amplification for the synthesis of patterned arrays PARG, RAD18, RAC2 ATAD2 2213/4885KDM4E 4005/4885ALDH1A1 1710/4885
US-20210214397-A1 CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS POLL, PCNA, POLG ATAD2 2136/4885KDM4E 4658/4885ALDH1A1 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.